The first-in-class activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, given the trade name Winrevair, has been cleared to improve exercise capacity, improve lung function, and reduce the risk of worsening clinical events in adults with PAH after a priority review.
PAH is a life-threatening disease, caused by the narrowing of blood vessels in the lungs, which is currently treated mainly with drugs that dilate the blood vessels, like endothelin antagonists and prostacyclin analogues, as well as phosphodiesterase inhibitors to increase blood flow through the lungs.
